A Case of a Patient with Atezolizumab-induced Encephalitis and Hepatocellular Carcinoma.
作者信息
Otomo Kakeru, Fujita Masashi
机构信息
Department of Gastroenterology, Fukushima Medical University School of Medicine, Japan.
出版信息
Intern Med. 2025 Jul 1;64(13):2089. doi: 10.2169/internalmedicine.4865-24. Epub 2024 Dec 5.
Abstract
摘要
相似文献
1
A Case of a Patient with Atezolizumab-induced Encephalitis and Hepatocellular Carcinoma.
Intern Med. 2025 Jul 1;64(13):2089. doi: 10.2169/internalmedicine.4865-24. Epub 2024 Dec 5.
2
Patient with Atezolizumab-induced Encephalitis in Hepatocellular Carcinoma.
Intern Med. 2025 Apr 15;64(8):1181-1187. doi: 10.2169/internalmedicine.4321-24. Epub 2024 Sep 11.
3
Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma-a multicentric study.
BMC Cancer. 2025 Jul 1;25(1):1026. doi: 10.1186/s12885-025-14400-9.
4
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.
J Hepatol. 2025 Jun;82(6):1036-1049. doi: 10.1016/j.jhep.2024.12.016. Epub 2024 Dec 19.
5
The use of durvalumab and tremelimumab after atezolizumab and bevacizumab in patients with hepatocellular carcinoma: case report and literature review.
Immunotherapy. 2025 Jul 28:1-8. doi: 10.1080/1750743X.2025.2539064.
6
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
J Cancer Res Clin Oncol. 2023 Aug;149(10):7565-7577. doi: 10.1007/s00432-023-04678-2. Epub 2023 Mar 28.
7
Evaluating the cost-effectiveness of atezolizumab-bevacizumab in advanced hepatocellular carcinoma: Insights from Taiwan.
J Food Drug Anal. 2025 Jun 13;33(2):163-171. doi: 10.38212/2224-6614.3542.
8
Tumor-suppressing multi-enterobacteria and PD-1/PD-L1 immune checkpoint inhibitor combination improves the outcome of hepatocellular carcinoma therapy.
Front Immunol. 2025 Jun 20;16:1598436. doi: 10.3389/fimmu.2025.1598436. eCollection 2025.
9
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.
J Cancer Res Clin Oncol. 2023 Aug;149(9):5591-5602. doi: 10.1007/s00432-022-04512-1. Epub 2022 Dec 13.
10
Retrospective Multicentre Real-Life Study Evaluating the Efficacy of Atezolizumab Combined with Bevacizumab for the Treatment of Metastatic Hepatocellular Carcinoma: HIREAL Study.
J Hepatocell Carcinoma. 2025 Jul 1;12:1279-1286. doi: 10.2147/JHC.S521130. eCollection 2025.
本文引用的文献
1
Before a Diagnosis of Atezolizumab and Bevacizumab-associated Encephalitis Is Made, all other Possible Causes Should be Ruled Out.
Intern Med. 2025 Jul 1;64(13):2088. doi: 10.2169/internalmedicine.4744-24. Epub 2024 Dec 5.
2
Patient with Atezolizumab-induced Encephalitis in Hepatocellular Carcinoma.
Intern Med. 2025 Apr 15;64(8):1181-1187. doi: 10.2169/internalmedicine.4321-24. Epub 2024 Sep 11.
3
A clinical approach to diagnosis of autoimmune encephalitis.
Lancet Neurol. 2016 Apr;15(4):391-404. doi: 10.1016/S1474-4422(15)00401-9. Epub 2016 Feb 20.
4
Non-convulsive status epilepticus and non-convulsive seizures in neurological ICU patients.
Neurocrit Care. 2015 Apr;22(2):202-11. doi: 10.1007/s12028-014-0070-0.
5
The epidemiology of convulsive and nonconvulsive status epilepticus.
Epilepsia. 2007;48 Suppl 8:82-4. doi: 10.1111/j.1528-1167.2007.01359.x.
Zotero 插件